Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease

Core Insights - Grifols has presented proof-of-concept data from its Chronos-PD program, indicating that biological changes in individuals with Parkinson's disease can occur more than a decade prior to clinical diagnosis, which may lead to advancements in early detection and intervention [1][4][9] Group 1: Chronos-PD Program - The Chronos-PD program, developed by Grifols' subsidiary Alkahest, aims to identify early signs of Parkinson's disease years before clinical diagnosis by utilizing plasma samples collected over 15 years [3][9] - The program employs AI, advanced proteomics, and real-world data to identify biomarkers that could predict disease risk and inform future treatments [3][4] Group 2: Research Findings - The proof-of-concept study analyzed over 2,600 longitudinal plasma samples and measured more than 25,000 protein types, making it the most comprehensive longitudinal proteomic study in Parkinson's disease to date [4][5] - Researchers confirmed previously discovered PD biomarkers and identified novel early biomarkers, including significant modulation of the CXCL12–cell adhesion molecules–integrin axis, which is linked to neuroinflammation in PD [5][6] Group 3: Implications for Early Detection - Current diagnostic methods for Parkinson's disease often detect the disorder too late to slow its progression, highlighting the urgent need for early detection biomarkers [7] - The Chronos-PD program shifts the focus from symptom-based evaluation to molecular trajectory profiling, potentially accelerating the development of early detection and intervention tools [11] Group 4: Grifols' Commitment and Resources - Grifols has one of the world's largest collections of biospecimens, with over 100 million proprietary plasma samples, which can be utilized for research across various diseases [10][12] - The company is dedicated to improving health outcomes through innovation in plasma-derived medicines and biopharmaceuticals, focusing on chronic, rare, and prevalent conditions [13][16]